Imperial College London
Portrait Picture

MrMikaelSodergren

Faculty of Medicine, Department of Surgery & Cancer

Clinical Senior Lecturer in Hepatopancreatobiliary Surgery
 
 
 
//

Contact

 

m.sodergren

 
 
//

Location

 

BN2/13Block B Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Kawka:2021:10.1002/jcph.1961,
author = {Kawka, M and Erridge, S and Holvey, C and Coomber, R and Usmani, A and Sajad, M and Michael, P and Rucker, J and Sodergren, M},
doi = {10.1002/jcph.1961},
journal = {Journal of Clinical Pharmacology},
pages = {1545--1554},
title = {Clinical outcome data of first cohort of chronic pain patients treated with cannabis-based sublingual oils in the United Kingdom – analysis from the UK Medical Cannabis Registry},
url = {http://dx.doi.org/10.1002/jcph.1961},
volume = {16},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Cannabis-based medicinal products (CBMPs) are an emerging therapeutic option in the management of primary chronic pain, utilizing the role of the endocannabinoid system in modulating central and peripheral pain processes. Despite promising pre-clinical data there is a paucity of high-quality evidence to support the use of CBMPs for chronic pain. This study aimed to investigate the health-related quality of life outcomes of patients with chronic pain who were prescribed CBMP oil preparations (Adven®, Curaleaf International)This study is a case-series of patients from the UK Medical Cannabis Registry, who were treated with CBMP oils for an indication of chronic pain. The primary outcomes were the changes in Brief Pain Inventory short-form (BPI), Short-form McGill Pain Questionnaire-2 (SF-MPQ-2), Visual Analogue Scale (VAS) Pain, General Anxiety Disorder-7 (GAD-7), Sleep Quality Scale (SQS), and EQ-5D-5L, at 1, 3, and 6 months.110 patients were included. Significant improvements in SQS, EQ-5D-5L pain and discomfort subscale, and Brief Pain Inventory Interference Subscale (p<0.05) at 1, 3, and 6 months were demonstrated. There were no notable differences between cannabis naïve and previous cannabis users in quality-of-life outcomes. The adverse event incidence was 30.0%, with most (n=58, 92.1%) adverse events being mild or moderate in intensity.Treatment of chronic pain with Adven® CBMP oils was associated with an improvement in pain-specific outcomes, HRQoL and self-reported sleep quality. Relative safety was demonstrated over medium-term prescribed use. Whilst these findings must be treated with caution considering the limitations of study design, they can inform future clinical trials.
AU  - Kawka,M
AU  - Erridge,S
AU  - Holvey,C
AU  - Coomber,R
AU  - Usmani,A
AU  - Sajad,M
AU  - Michael,P
AU  - Rucker,J
AU  - Sodergren,M
DO  - 10.1002/jcph.1961
EP  - 1554
PY  - 2021///
SN  - 1552-4604
SP  - 1545
TI  - Clinical outcome data of first cohort of chronic pain patients treated with cannabis-based sublingual oils in the United Kingdom – analysis from the UK Medical Cannabis Registry
T2  - Journal of Clinical Pharmacology
UR  - http://dx.doi.org/10.1002/jcph.1961
UR  - https://accp1.onlinelibrary.wiley.com/doi/10.1002/jcph.1961
UR  - http://hdl.handle.net/10044/1/91666
VL  - 16
ER  -
Download